Your browser doesn't support javascript.
loading
Evaluation and optimization of a clinical pharmacist driven transitions of care model for malignant hematology.
Wind, Lucas S; Knight, Thomas G; Auten, Jessica J; Bates, Jill S; Marucci, Leonardo; Creedle, Crista J; Foster, Matthew C; Muluneh, Benyam.
Afiliação
  • Wind LS; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
  • Knight TG; University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
  • Auten JJ; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Bates JS; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
  • Marucci L; University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
  • Creedle CJ; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
  • Foster MC; University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
  • Muluneh B; Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
J Oncol Pharm Pract ; 27(2): 283-287, 2021 Mar.
Article em En | MEDLINE | ID: mdl-32290764
ABSTRACT

PURPOSE:

To implement and optimize a pilot transitions of care model for scheduled chemotherapy admissions in patients with hematologic malignancies at our institution.

Methodology:

We utilized the plan-do-study-act (PDSA) quality improvement technique to prospectively measure success of interventions related to improving transitions of care processes that occurred in multiple stages including development of standardized operating procedures, electronic medical record documentation, and education to the malignant hematology multidisciplinary group. Chart review was performed retrospectively for at least nine patients per PDSA cycle. Areas of intervention addressed and measured regarding communication between the ambulatory care and acute care settings included admission purpose, processes related to insurance benefits investigations for specialty medications required in the post-discharge setting, and plan for growth factors, prophylactic antimicrobials, and follow-up.Results and

conclusions:

We included 28 patients and performed a total of three PDSA cycles demonstrating specific improvements in communication regarding status of benefits investigations performed for specialty medications prior to admission, resolution of these benefits investigations at various time points, improvement in efficient use of the electronic medical record for chemotherapy orders, and patient instructions for appropriate use of prophylactic antimicrobials. Although improvement was noted initially with prescribing of discharge antiemetics and antimicrobials, regression to baseline was noted with the third PDSA cycle.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transferência de Pacientes / Neoplasias Hematológicas / Melhoria de Qualidade / Benefícios do Seguro / Seguro Saúde Tipo de estudo: Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transferência de Pacientes / Neoplasias Hematológicas / Melhoria de Qualidade / Benefícios do Seguro / Seguro Saúde Tipo de estudo: Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos